Mar 1 |
Sarepta Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
|
Feb 29 |
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Feb 29 |
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
|
Feb 29 |
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
|
Feb 29 |
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
|
Feb 29 |
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
Feb 28 |
Sarepta Therapeutics Non-GAAP EPS of $0.82 beats by $0.45, revenue of $396.78M beats by $10.62M
|
Feb 28 |
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
|